A A Al'-Nekhmi

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Ninety-six patients with unresectable or metastatic colorectal cancer received first-line chemotherapy plus bevacizumab. The purpose of our study was to evaluate the safety and efficacy of the therapy. Median relapse-free survival lasted 10.4 months. Addition of bevacizumab was well tolerated and may be recommended for clinical use.
  • 1